



# i-MEET

## NEXT GENERATION

Multidisciplinary European Endovascular Therapy

# Debate - There is no U-turn for the endovascular treatments

On behalf of USZ vascular specialists

Felice Pecoraro, MD

# Disclosure of Interest

Speaker name: Felice Pecoraro

- I do not have any potential conflict of interest

# 1988-First T-EVAR case

УДК 616.832.007.84.001.2.009.815.2

И. Л. Володос, И. П. Карпович, В. Е. Шелани, В. И. Троля, Л. Ф. Иго-  
ченко, Л. С. Кернсет, А. С. Ломова, В. И. Кузнец, А. И. Савков,  
Г. И. Гагарин

**СЛУЧАЙ ДИСТАНЦИОННОГО ЧРЕЗБЕДРЕННОГО  
ЭНДОПРОТЕЗИРОВАНИЯ ГРУДНОЙ АОРТЫ  
САМОФИКСИРУЮЩИМСЯ СИНТЕТИЧЕСКИМ ПРОТЕЗОМ  
ПРИ ТРАВМАТИЧЕСКОЙ АНЕВРИЗМЕ**

Харьковский ИИИГ общей и неотложной хирургии (дир. — проф. В. Т. Забуж)



Рис. 1. Аортограмма больного Б.  
Контрастирована аневризмальная аорта на уровне X—XI  
грудных позвонков с периферическим течением в  
стенках на 50% на уровне VIII—IX грудных по-  
звонков.



Рис. 3. Рентгенограмма грудной клетки боль-  
ного Б. через 2 мес после операции.  
Фиксируемые элементы проследуют на том же уров-  
не.



Рис. 2. Аортограмма больного Б. после раз-  
мещения эндопротеза.  
Видим спонтанный проток на уровне VIII—XI  
грудных позвонков, в тесной фиксации про-  
теза на уровне VIII—XI грудных позвонков. Стенка  
аорты под аневризматическим мешком не контрасти-  
руется.

Volodos IL, et al. A case of distal transcatheter endovascular prosthesis of the thoracic artery using a self-fixing synthetic prosthesis in traumatic aneurysm. *Grain khir* 1988; 634-5

# N. Volodos



## 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases

Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult

The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC)

of the European Society of Cardiology (ESC)

The Task Force for the Diagnosis and Treatment of Aortic Diseases

and abdominal aorta of the adult

TEVAR should be considered in patients who have a descending TAA with a maximal diameter  $\geq 55$  mm. When surgery is the only option, it should be considered in patients with a maximal diameter  $\geq 60$  mm. Lower thresholds can be considered in patients with Marfan syndrome.

### Recommendations for (contained) rupture the thoracic aortic aneurysm

| Recommendations                                                                                                                     | Class <sup>a</sup> | Level <sup>b</sup> |
|-------------------------------------------------------------------------------------------------------------------------------------|--------------------|--------------------|
| In patients with suspected rupture of the TAA, emergency CT angiography for diagnosis confirmation is recommended.                  | I                  | C                  |
| In patients with acute contained rupture of TAA, urgent repair is recommended.                                                      | I                  | C                  |
| If the anatomy is favourable and the expertise available, <u>endovascular repair (TEVAR) should be preferred over open surgery.</u> | I                  | C                  |

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

CT = computed tomography; TAA = thoracic aortic aneurysm;


TEVAR = thoracic endovascular aortic repair.

## Survival After Open Versus Endovascular Thoracic Aortic Aneurysm Repair in an Observational Study of the Medicare Population

Philip P. Goodney, MD, MS; Lori Travis, MS; F. Lee Lucas, PhD; Mark F. Fillinger, MD;  
David C. Goodman, MD, MS; Jack L. Cronenwett, MD; David H. Stone, MD

David C. Goodman, MD, MS; Jack L. Cronenwett, MD; David H. Stone, MD  
Philip P. Goodney, MD, MS; Lori Travis, MS; F. Lee Lucas, PhD; Mark F. Fillinger, MD

MEDICAL RESEARCH



(Circulation. 2011;124:2661-2669.)

# Long-term comparison of thoracic endovascular aortic repair (TEVAR) to open surgery for the treatment of thoracic aortic aneurysms

Nimesh D. Desai, MD, PhD, Kristen Burtch, BS, William Moser, MS, Pat Moeller, BS, Wilson Y. Szeto, MD, Alberto Pochettino, MD, Edward Y. Woo, MD, Ronald M. Fairman, MD, and Joseph E. Bavaria, MD

Joseph E. Bavaria, MD

Wilson Y. Szeto, MD, Alberto Pochettino, MD, Edward Y. Woo, MD, Ronald M. Fairman, MD, and Nimesh D. Desai, MD, PhD, Kristen Burtch, BS, William Moser, MS, Pat Moeller, BS






FIGURE 2. Long-term survival. TEVAR, Thoracic endovascular aortic repair.

# EVEM Panel TEVAR


4<sup>th</sup> quarter 2014 – 3<sup>rd</sup> Quarter 2015

Chart 3: TAA trend over time, TEVAR & Open Repair



|                | Endovascular Procedures | Surgical Procedures |
|----------------|-------------------------|---------------------|
| AAA            | 6,895                   | 3,279               |
| <b>TAA</b>     | <b>1,538</b>            | <b>611</b>          |
| Aorto-Iliac    | 27,453                  | 4,163               |
| Fem-Pop        | 51,061                  | 8,048               |
| <b>Overall</b> | <b>86,947</b>           | <b>16,101</b>       |

Chart 4: TEVAR vs Open Repair Split






# Endovascular stent grafting versus open surgical repair of descending thoracic aortic aneurysms in low-risk patients: A multicenter comparative trial

Joseph E. Bavaria, MD,<sup>a</sup> Jehangir J. Appoo, MD,<sup>a,b</sup> Michel S. Makaroun, MD,<sup>c</sup> Joel Verter, PhD,<sup>d</sup> Zi-Fan Yu, ScD,<sup>d</sup> and R. Scott Mitchell, MD,<sup>e</sup> for the Gore TAG Investigators\*

and R. Scott Mitchell, MD,<sup>e</sup> for the Gore TAG Investigators\*

Joseph E. Bavaria, MD,<sup>a</sup> Jehangir J. Appoo, MD,<sup>a,b</sup> Michel S. Makaroun, MD,<sup>c</sup> Joel Verter, PhD,<sup>d</sup> Zi-Fan Yu, ScD,<sup>d</sup> and R. Scott Mitchell, MD,<sup>e</sup> for the Gore TAG Investigators\*

|                                                               | Endovascular group | Open surgical group | P value |   |
|---------------------------------------------------------------|--------------------|---------------------|---------|---|
| Mortality: 30 d or in hospital                                | 2.1% (n = 3)       | 11.7% (n = 11)      | .004    | ← |
| Respiratory failure*                                          | 4%                 | 20%                 | <.001   | ← |
| Postoperative MI                                              | 0%                 | 1%                  | .40     |   |
| Renal failure†                                                | 1%                 | 13%                 | .01     | ← |
| Wound infection/dehiscence                                    | 4%                 | 11%                 | .07     |   |
| GI complication (ileus, bowel ischemia, or bowel obstruction) | 2%                 | 6%                  | .16     |   |
| Peripheral vascular complications‡                            | 14%                | 4%                  | .015    | ← |
| Neurologic complications                                      |                    |                     |         |   |
| CVA                                                           | 4% (n = 5)         | 4% (n = 4)          | 1.00    |   |
| Paraplegia/paraparesis                                        | 3% (n = 4)         | 14% (n = 13)        | .003    | ← |
| Mean ICU length of stay (d)                                   | 2.6 ± 14.6         | 5.2 ± 7.2           | <.001   | ← |
| Mean length of hospital stay (d)                              | 7.4 ± 17.7         | 14.4 ± 12.8         | <.001   | ← |



|                           |     |     |     |    |
|---------------------------|-----|-----|-----|----|
| Endograft (n)             | 140 | 134 | 105 | 79 |
| Open Surgical Control (n) | 94  | 85  | 62  | 49 |




## Long-term comparison of thoracic endovascular aortic repair (TEVAR) to open surgery for the treatment of thoracic aortic aneurysms

Nimesh D. Desai, MD, PhD, Kristen Burch, BS, William Moser, MS, Pat Moeller, BS, Wilson Y. Szeto, MD, Alberto Pochettino, MD, Edward Y. Woo, MD, Ronald M. Fairman, MD, and Joseph E. Bavaria, MD

Joseph E. Bavaria, MD

Wilson Y. Szeto, MD, Alberto Pochettino, MD, Edward Y. Woo, MD, Ronald M. Fairman, MD, and Nimesh D. Desai, MD, PhD, Kristen Burch, BS, William Moser, MS, Pat Moeller, BS, and Joseph E. Bavaria, MD



## Results of Thoracic Endovascular Aortic Repair 6 Years After United States Food and Drug Administration Approval

Asad A. Shah, MD, Michael E. Barfield, MD, Nicholas D. Andersen, MD, Judson B. Williams, MD, Julie A. Shah, RN, BSN, Jennifer M. Hanna, MD, MBA, Richard L. McCann, MD, and G. Chad Hughes, MD

Department of Surgery, Duke University Medical Center, Durham, North Carolina

Department of Surgery, Duke University Medical Center, Durham, North Carolina

G. Chad Hughes, MD

Asad A. Shah, MD, Michael E. Barfield, MD, Nicholas D. Andersen, MD, Judson B. Williams, MD, Julie A. Shah, RN, BSN, Jennifer M. Hanna, MD, MBA, Richard L. McCann, MD, and G. Chad Hughes, MD




Fig 1.  
Kaplan-Meier curve demonstrates an 84% freedom from reintervention at 6 years after thoracic endovascular aortic repair.

# Superior nationwide outcomes of endovascular versus open repair for isolated descending thoracic aortic aneurysm in 11,669 patients

Raja R. Gopaldas, MD,<sup>a,b</sup> Joseph Huh, MD,<sup>a,b</sup> Tam K. Dao, PhD,<sup>c</sup> Scott A. LeMaire, MD,<sup>a,b</sup>  
Danny Chu, MD,<sup>a,d</sup> Faisal G. Bakaeen, MD,<sup>a,d</sup> and Joseph S. Coselli, MD<sup>a,b</sup>

**TABLE 1. Patient demographics and baseline characteristics**




| Characteristic     | OAR (n = 9106) | TEVAR (n = 2563) | $\chi^2$ or <i>t</i> | <i>P</i> value | Effect size* |
|--------------------|----------------|------------------|----------------------|----------------|--------------|
| Age (y)            | 60.2 ± 14.2    | 69.5 ± 12.7      | 31.888               | < .001         | 0.67         |
| Elective admission | 7660 (84.1%)   | 2158 (84.2%)     | 0.009                | .9             | NA           |

**TABLE 2. Patient comorbidities**

| Comorbidity                      | OAR (n = 9106) | TEVAR (n = 2563) | $\chi^2$ | <i>P</i> value | $\phi$ |
|----------------------------------|----------------|------------------|----------|----------------|--------|
| Chronic PVD                      | 368 (4.0%)     | 564 (22.0%)      | 878.398  | < .001         | 0.274  |
| Previous MI                      | 10 (0.1%)      | 10 (0.4%)        | 9.189    | .005           | 0.028  |
| Previous CHF                     | 1441 (15.8%)   | 264 (10.3%)      | 48.896   | < .001         | 0.065  |
| Previous cerebrovascular disease | 278 (3.1%)     | 205 (8.0%)       | 123.315  | < .001         | 0.103  |
| Chronic pulmonary disease        | 1306 (14.4%)   | 881 (34.4%)      | 527.618  | < .001         | 0.213  |
| Rheumatic disease                | 110 (1.2%)     | 42 (1.6%)        | 2.888    | .09            | 0.016  |
| Peptic ulcer disease             | 25 (0.3%)      | 24 (0.9%)        | 20.957   | < .001         | 0.042  |
| Mild liver disease               | 40 (0.4%)      | 5 (0.2%)         | 3.104    | .1             | 0.016  |
| Diabetes mellitus                | 854 (9.4%)     | 352 (13.7%)      | 40.943   | < .001         | 0.059  |
| Diabetic complications           | 63 (0.7%)      | 25 (1.0%)        | 2.149    | .2             | 0.014  |
| Hemiplegia or paraplegia         | 61 (0.7%)      | 26 (1.0%)        | 3.209    | .09            | 0.017  |
| Chronic kidney disease           | 388 (4.3%)     | 313 (12.2%)      | 224.128  | < .001         | 0.139  |
| HIV                              | 10 (0.1%)      | 0                | 2.817    | .1             | 0.016  |
| Cancer                           | 120 (1.3%)     | 36 (1.4%)        | 0.116    | .7             | 0.003  |
| Metastatic cancer                | 18 (0.2%)      | 5 (0.2%)         | 0.001    | 1.0            | 0.001  |

**TABLE 3. Unadjusted outcomes of TEVAR versus OAR**

| Outcome                                            | OAR<br>(n = 9106) | TEVAR<br>(n = 2563) | P<br>value | Effect<br>size |
|----------------------------------------------------|-------------------|---------------------|------------|----------------|
| Died during hospitalization                        | 209 (2.3%)        | 59 (2.3%)           | 1.0        | 0*             |
| Complications per patient                          | 0.51 ± 0.79       | 0.33 ± 0.67         | < .001     | 0.7†           |
| Any complication                                   | 3428 (37.6%)      | 588 (22.9%)         | < .001     | 0.128*         |
| Length of stay (d)                                 | 8.77 ± 7.9        | 7.6 ± 11.1          | < .001     | 0.13†          |
| Routine discharge                                  | 4126 (45.3%)      | 1671 (65.2%)        | < .001     | 0.188*         |
| Intraoperative/procedure-<br>related complications | 2066 (22.7%)      | 294 (11.5%)         | < .001     | 0.116*         |
| Deep venous thrombosis                             | 38 (0.4%)         | 50 (2.0%)           | < .001     | 0.073*         |
| Infections                                         | 488 (5.4%)        | 140 (5.5%)          | .8         | 0.002*         |
| Neurologic complications                           | 217 (2.4%)        | 64 (2.5%)           | .7         | 0.003*         |
| Pulmonary embolism                                 | 32 (0.4%)         | 6 (0.2%)            | .4         | −0.009*        |
| Respiratory complications                          | 951 (10.4%)       | 110 (4.3%)          | < .001     | −0.089*        |
| Renal complications                                | 535 (5.9%)        | 157 (6.1%)          | .6         | 0.004*         |





Prof G. Melissano

**NO DOUBT  
TEVAR IS THE FIRST CHOICE**

# Limitation - Branch Vessels


## ◆ CLINICAL INVESTIGATION ◆

## Periscope Endograft Technique to Revascularize the Left Subclavian Artery During Thoracic Endovascular Aortic Repair


Mario Lachat, MD<sup>1</sup>; Dieter Mayer, MD<sup>1</sup>; Thomas Pfammatter, MD<sup>2</sup>; Frank J. Criado, MD<sup>3</sup>; Zoran Rancic, MD, PhD<sup>1</sup>; Thomas Larzon, MD, PhD<sup>4</sup>; Frank J. Veith, MD<sup>1,5</sup>; and Felice Pecoraro, MD<sup>1,6</sup>

and Felice Pecoraro, MD<sup>1,6</sup>  
 Zoran Rancic, MD, PhD<sup>1</sup>; Thomas Larzon, MD, PhD<sup>4</sup>; Frank J. Veith, MD<sup>1,5</sup>;  
 Mario Lachat, MD<sup>1</sup>; Dieter Mayer, MD<sup>1</sup>; Thomas Pfammatter, MD<sup>2</sup>; Frank J. Criado, MD<sup>3</sup>;

### THORACIC ENDOVASCULAR AORTIC REPAIR





## Aortic stentgraft landing in **zone 2**







## Parallel Graft (chimney, periscope)




## Parallel Graft (chimney, periscope)



chimney




periscope






CA Bypass

LCCA chimney











# Innominate branch

## Module 1




### Nexus™ Delivery System

Nexus' low-profile, 20Fr delivery system makes this EVAR option available for a wide range of patients




Module 1


Ascending fenestration








± Supraaortic Fenestration









al CTA




# Debranching + TEVAR








# Gore Hybridgraft (Carotid arteries)




# EVAR with periscope endograft on LSA












# Periscope graft to extend distal landing zone in ruptured thoracoabdominal aneurysms with short distal necks

Zoran Rancic, MD, PhD,<sup>a</sup> Thomas Pfammatter, MD,<sup>b</sup> Mario Lachat, MD,<sup>a</sup> Lukas Hechelhammer, MD,<sup>b</sup> Thomas Frauenfelder, MD,<sup>b</sup> Frank J. Veith, MD,<sup>c,d</sup> Frank J. Criado, MD,<sup>c</sup> and Dieter Mayer, MD,<sup>a</sup> *Zurich, Switzerland; New York, NY; and Baltimore, Md*

Endovascular aneurysm repair (EVAR) of ruptured thoracoabdominal aortic aneurysms may be compromised or even impossible due to short proximal and/or distal necks or landing zones, respectively. Supra-aortic branches may limit the proximal anchorage and visceral or renal arteries the distal anchorage of endografts. While solutions have been proposed to overcome the problem of a short proximal neck, no technique has been described that solves the problem of a short distal neck. We present the “periscope technique,” which allows extension of the distal landing zone and complete endovascular treatment of ruptured thoracoabdominal aneurysms with short distal necks using devices already stocked in most centers performing EVAR procedures. (J Vasc Surg 2010;51:1293-6.)



2 reversed chimneys  
(Periscopes)

# TEVAR LT results: 18 years TAI

TEVAR (7.7.1998)



4.12.2015



# Connective Tissue diseases


- Surgery should be preferred over TEVAR
- TEVAR could be employed as a bridge to surgical therapy in emergent setting for initial stabilization.

# Sister in law


- 42 yo, Marfan
- 4.2.2010: «sudden death»
  - Root and ascending replacement & mitral valve repair
- 2.3.2010: AICD
- 10.6.2010: Acute B type Dissection
- 23.6.2010: TEVAR
- 2.3.2011: redo TEVAR

FUP 30 months post EVAR





30 months FUP



30 months FUP

# Costs

*J Vasc Surg.* 2015 March ; 61(3): 596–603. doi:10.1016/j.jvs.2014.09.009.

## Cost Analysis of Endovascular versus Open Repair in the Treatment of Thoracic Aortic Aneurysms

Jacob R. Gillen, MD, Basil W. Schaheen, MD, Kenan W. Yount, MD, MBA, Kenneth J. Cherry, MD, John A. Kern, MD, Irving L. Kron, MD, Gilbert R. Upchurch Jr, MD, and Christine L. Lau, MD, MBA


Department of Surgery, Division of Thoracic and Cardiovascular Surgery, University of Virginia Health System, Charlottesville, VA, USA

*Eur J Vasc Endovasc Surg* 29, 28–34 (2005)

doi:10.1016/j.jejvs.2004.10.003, available online at <http://www.sciencedirect.com> on **SCIENCE @ DIRECT®**

## Mid-term Survival and Costs of Treatment of Patients with Descending Thoracic Aortic Aneurysms; Endovascular vs. Open Repair: a Case-control Study

G.J. Glade,<sup>1</sup> A.C. Vahl,<sup>1\*</sup> W. Wisselink,<sup>2</sup> M.A.M. Linsen<sup>2</sup> and R. Balm<sup>3</sup>



**Figure 1.**  
Cost Forecast of TEVAR vs. Open TAA Repair over time. Each forecast reflects the mean surrounded by error bars reflecting the interquartile range.

Table 5. Costs per patient operated by endovascular or open repair



|                |                                             | Endo (€) | Open (€) | Costs calculation remarks                                                                                   |
|----------------|---------------------------------------------|----------|----------|-------------------------------------------------------------------------------------------------------------|
| Peri-operative | Operation costs. Including anaesthesia time | 1333     | 4000     | Endo: €500/h, Open: €800/h. including distal perfusion and personnel                                        |
|                | Prosthesis                                  | 10,000   | 500      | Two Talent stents/patient Dacron graft for open                                                             |
|                | Specialists                                 | 600      | 1000     | Endo: surgeon and radiologist; open surgeon and cardiothoracic surgeon                                      |
|                | Radiological investigations                 | 2000     | 400      |                                                                                                             |
|                | Laboratory                                  | 200      | 200      |                                                                                                             |
| Nursing costs  | Intensive care                              | 2310     | 18,150   | Mean stay see text                                                                                          |
|                | Ward                                        | 1620     | 3420     | Mean stay see text                                                                                          |
| Post-operative | Paraplegia rehabilitation                   | 2600     | 6100     | Costs of life long care (rehospitalisation etc.) not included. Calculation according to percentages in text |
| Total          |                                             | 20,663   | 33,770   |                                                                                                             |

# Conclusion

- TEVAR has **lower perioperative mortality and morbidity** compared to OSR
- TEVAR has **lower costs** compared to OSR
- TEVAR has **superior QOL** when compared to OSR
- TEVAR has **lower/similar SCI** incidence compared to OSR
- **Survival long-term outcomes are similar** for TEVAR and OSR
- **CTDs** still represent **indications to OSR**
- Most of the **reinterventions after TEVAR** are performed **endovascularly**

# Surgical trauma TEVAR VS OSR

## Patient's treatment preference



**SORRY... BUT**

**THERE IS NO U-TERM FOR TEVAR!!!**

**BYE-BYE OPEN**

**THANK YOU FOR YOUR ATTENTION**

[felice.pecoraro@unipa.it](mailto:felice.pecoraro@unipa.it)

